In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients. It’s another step in a process of changing rules put in place decades ago.
In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients. It’s another step in a process of changing rules put in place decades ago.
More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the multitarget alliance aims to discover and develop novel treatments for Parkinson’s disease and another neurodegenerative indication.
More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the multitarget alliance aims to discover and develop novel treatments for Parkinson’s disease and another neurodegenerative indication.
After two years of developing its platform, Vesalius Therapeutics Inc. now has $75 million in its pocket from Flagship Pioneering to understand and treat the diseases that account for 90% of the world’s illnesses. To resolve this massive amount of biological and industry complexity, Doug Cole, Vesalius’ chairman and co-founder and Flagship’s managing partner, noted the distinction between illness and disease. “Illness is what bothers you, it’s the experience of being sick and what the doctor might find when you’re examined,” Cole told BioWorld. “Disease is the mechanistic problem with the biology underlying the illness.”
